Description: Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Home Page: www.eupraxiapharma.com
2067 Cadboro Bay Road
Victoria,
BC
V8R 5G4
Canada
Phone:
250 590 3968
Officers
| Name | Title |
|---|---|
| Dr. James A. Helliwell FRCPC, M.D. | CEO & Director |
| Mr. Bruce G. Cousins C.A., CPA | President & CFO |
| Dr. Amanda Malone Ph.D. | Chief Scientific Officer & COO |
| Mr. Paul Anthony Brennan B.Sc., M.Sc. | Chief Business Officer |
| Dr. Mark M. Kowalski M.D., Ph.D. | Chief Medical Officer |
| Dr. Rahul Sarugaser M.B.A., Ph.D. | Executive Vice President of Corporate Development |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.1965 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 29 |